Respiratory Domain Conference Coverage

Objective

Idiopathic Pulmonary Fibrosis (IPF) is a progressive and life-threatening interstitial lung disease (ILD) characterized by declining lung function and high morbidity. With limited therapeutic options and a complex treatment landscape, timely intervention and continuous monitoring of scientific advancements are crucial.

Our client, currently developing a novel therapy for IPF, engaged DelveInsight to deliver comprehensive conference coverage across key global respiratory events: ATS, ERS, JRS, and the IPF Summit 2024. Their goal was to stay informed on emerging innovations, understand evolving clinical trial designs, evaluate mechanisms of action (MOAs), and monitor competitor developments within the expanding yet challenging IPF pipeline.

Methods

To provide robust insights into the fast-evolving IPF landscape, DelveInsight employed a multi-layered research approach:

• Pre-Conference Analysis: Reviewed detailed program agendas and abstracts to identify high-priority sessions, key presenters, competitive companies, and scientific themes aligned with the client’s strategic objectives.
• On-Site Insights Collection: Attended scientific presentations, symposia, and panel discussions to capture real-time insights on clinical trial outcomes, biomarker advancements, treatment strategies, and emerging technologies.
• Expert Engagements: Conducted follow-up interviews with presenters, respiratory physicians, researchers, KOLs, industry delegates, and clinical investigators to gather deeper perspectives on unmet needs and innovation gaps.
• Media & Publication Review: Analyzed conference-related press releases, journal articles, and scientific updates to ensure comprehensive coverage.
• Social Media & Sentiment Tracking: Leveraged live-tweeting and social analytics to map the real-time pulse of the IPF community, including practitioner sentiment, patient group opinions, and payer considerations, to evaluate the broader impact of the event.
  
  

Findings

• Engagement with Global IPF Experts: DelveInsight interacted with leading respiratory specialists, clinical researchers, and patient advocacy groups, gaining multi-stakeholder viewpoints on the evolving IPF treatment paradigm.
• Key Challenges Identified: Experts highlighted the persistent challenges in improving patient quality of life, managing symptoms, and navigating limited therapeutic efficacy despite available antifibrotic therapies.
  Clinical Trial Intelligence: Comprehensive review of multiple pipeline programs enabled a comparative assessment of efficacy endpoints, safety data, MOAs, and trial design innovations across emerging IPF therapies.
• KOL-Driven Insights: Discussions with KOLs revealed future-focused trends, including interest in novel efficacy markers, precision medicine approaches, and biomarker-guided treatments.
• Brand & Asset Perception Mapping: Sentiment analysis uncovered meaningful insights into how experts perceive the client’s drug candidate, influencing its potential positioning and future adoption.
• Panel Discussion Takeaways: Panels emphasized the growing importance of prognostic biomarkers, patient stratification, and the shift toward personalized therapy to treat “the right patient at the right time.
  
  

Conclusion

DelveInsight delivered a comprehensive, insight-rich report summarizing the current and future IPF landscape, competitor activities, scientific advancements, and emerging therapeutic trends highlighted during major respiratory conferences.

Key deliverables included:

• A detailed assessment of IPF pipeline developments and technological innovations
• Non-biased scientific insights based on interactions with top global experts
• A high-level PowerPoint summary presented to the client’s senior leadership to guide strategic decision-making and next-step planning
  
  

To explore more about DelveInsight’s Conference Coverage Services, connect with our team for customized, real-time competitive intelligence and scientific monitoring.